International Journal of Cancer Management

Published by: Kowsar

Association Between Cytochrome 1B1*3 Polymorphism and the Breast Cancer in a Group of Iranian Women

Faezeh Kholousi Adab 1 , Zahra Tahmasebi Fard 2 , * and Mohammad Esmaeil Akbari 2
Authors Information
1 Department of Molecular and Cellular Sciences, Faculty of Advanced Sciences & Technology, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
2 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • Iranian Journal of Cancer Prevention: January 2017, 10 (1); e6428
  • Published Online: January 24, 2017
  • Article Type: Research Article
  • Received: April 17, 2016
  • Revised: March 24, 2016
  • Accepted: January 14, 2017
  • DOI: 10.17795/ijcp-6428

To Cite: Kholousi Adab F, Tahmasebi Fard Z, Esmaeil Akbari M. Association Between Cytochrome 1B1*3 Polymorphism and the Breast Cancer in a Group of Iranian Women, Int J Cancer Manag. 2017 ; 10(1):e6428. doi: 10.17795/ijcp-6428.

Copyright © 2017, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Safaei Keshtgar M, Rob S. Breast cancer [in Persian]. 1388; : 138-684
  • 2. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J. 2007; 13(4): 383-91[DOI][PubMed]
  • 3. Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer--a case-control study in Iran. Asian Pac J Cancer Prev. 2005; 6(3): 370-5[PubMed]
  • 4. Tonini G, Schiavon G, Fratto ME, Vincenzi B, Santini D. Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. Expert Opin Biol Ther. 2008; 8(2): 221-34[DOI][PubMed]
  • 5. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006; 13 Suppl 1: 15-24[DOI][PubMed]
  • 6. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 11(5): 489-92[PubMed]
  • 7. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT, et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J Histochem Cytochem. 1999; 47(11): 1457-64[DOI][PubMed]
  • 8. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 1997; 57(14): 3026-31[PubMed]
  • 9. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol. 2001; 41: 297-316[DOI][PubMed]
  • 10. Shoun H, Tanimoto T. Denitrification by the fungus Fusarium oxysporum and involvement of cytochrome P-450 in the respiratory nitrite reduction. J Biol Chem. 1991; 266(17): 11078-82[PubMed]
  • 11. Nelson D. Bacterial P450 Links, Estimate 90 Bacteria P450 Genes 2004;
  • 12. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 1996; 93(18): 9776-81[DOI][PubMed]
  • 13. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004; 95(1): 1-6[DOI][PubMed]
  • 14. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996; 56(13): 2979-84[PubMed]
  • 15. Xu W, Zhou Y, Hang X, Shen D. Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep. 2012; 39(3): 2821-9[DOI][PubMed]
  • 16. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet. 1998; 62(3): 573-84[DOI][PubMed]
  • 17. McLellan RA, Oscarson M, Hidestrand M, Leidvik B, Jonsson E, Otter C, et al. Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch Biochem Biophys. 2000; 378(1): 175-81[DOI][PubMed]
  • 18. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol. 2002; 61(3): 586-94[PubMed]
  • 19. Ahangar N, Masoumi S. Frequency Evaluation of Val432Leu (G4326C) Polymorphism of CYP1B1 Gene in a Healthy Population from Mazandaran Province, Iran. J Mazand Univ Med Sci. 2013; 23(106): 20-8
  • 20. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998; 58(22): 5038-41[PubMed]
  • 21. Pia S. Polymorphic low penetrance genes and breast cancer. 2007;
  • 22. Noguera NI, Tallano CE, Bragos IM, Milani AC. Modified salting-out method for DNA isolation from newborn cord blood nucleated cells. J Clin Lab Anal. 2000; 14(6): 280-3[PubMed]
  • 23. Wen W. Cytochrome P4501B1 and Catechol-O-ethyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis. J Cancer Epidemiol Biomarkers Prev. 2014; : 329-35
  • 24. Zangiabadi M, Moatari M, Tabatabaei H. Comparing the Effect of Teaching Breast Self-Examination by Peers and Health Care Personnel on Students Knowledge and Attitude [in Persian]. Iran J Med Edu. 2009; 2: 195-203
  • 25. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica. 1998; 28(12): 1129-65[DOI][PubMed]
  • 26. Lewis DF, Lake BG, George SG, Dickins M, Eddershaw PJ, Tarbit MH, et al. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology. 1999; 139(1-2): 53-79[PubMed]
  • 27. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res. 2003; 63(14): 3913-8[PubMed]
  • 28. Sharma M, Shubert DE, Sharma M, Lewis J, McGarrigle BP, Bofinger DP, et al. Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact. 2003; 146(3): 237-49[DOI][PubMed]
  • 29. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev. 2001; 10(3): 209-16[PubMed]
  • 30. Kumar V, Singh S, Ahmed RS, Banerjee BD, Ahmed T, Pasha ST. Frequency of common CYP1B1 polymorphic variations in Delhi population of Northern India. Environ Toxicol Pharmacol. 2009; 28(3): 392-6[DOI][PubMed]
  • 31. Listgarten J, Damaraju S, Poulin B, Cook L, Dufour J, Driga A, et al. Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res. 2004; 10(8): 2725-37[DOI][PubMed]
  • 32. Zheng W, Xie DW, Jin F, Cheng JR, Dai Q, Wen WQ, et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000; 9(2): 147-50[PubMed]
  • 33. Chen B, Qiu LX, Li Y, Xu W, Wang XL, Zhao WH, et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer. 2010; 70(3): 247-52[DOI][PubMed]
  • 34. Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, et al. Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer. 2010; 10: 511[DOI][PubMed]
  • 35. Bandi P. American Cancer Society 2009-2010;
  • 36. Napoli N, Rini GB, Serber D, Giri T, Yarramaneni J, Bucchieri S, et al. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. Bone. 2009; 44(3): 442-8[DOI][PubMed]
  • 37. Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis. 2003; 24(9): 1533-9[DOI][PubMed]
  • 38. Martinez-Ramirez OC, Perez-Morales R, Castro C, Flores-Diaz A, Soto-Cruz KE, Astorga-Ramos A, et al. Polymorphisms of catechol estrogens metabolism pathway genes and breast cancer risk in Mexican women. Breast. 2013; 22(3): 335-43[DOI][PubMed]
  • 39. Jiao H, Liu C, Guo W, Peng L, Chen Y, Martin FL. Association of CYP1B1 Polymorphisms with Breast Cancer: A Case-Control Study in the Han Population in Ningxia Hui Autonomous Region, P. R. China. Biomark Insights. 2010; 5: 21-7[PubMed]
  • 40. Zimarina TC, Kristensen VN, Imianitov EN, Bershtein LM. [Polymorphisms of CYP1B1 and COMT in breast and endometrial cancer]. Mol Biol (Mosk). 2004; 38(3): 386-93[DOI][PubMed]
  • 41. Liu F, Luo LM, Wei YG, Li B, Wang WT, Wen TF, et al. Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population. Gene. 2015; 564(1): 14-20[DOI][PubMed]
  • 42. Yu PJ, Chen WG, Feng QL, Chen W, Jiang MJ, Li ZQ. Association between CYP1B1 gene polymorphisms and risk factors and susceptibility to laryngeal cancer. Med Sci Monit. 2015; 21: 239-45[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments